Brabant pharmaceutical company Organon included in S&P 500 in New York

As of June 3, the originally Dutch pharmaceutical company Organon will be included in the broad American stock market index S&P 500, which includes the 500 largest American companies. Organon gets its own listing following the spin-off of US drug company Merck, known outside of North America as MSD.

Merck, which incorporated Organon in 2009, already announced last year that it wanted to split off parts under the name Organon. This will soon include the branch that deals with women’s health. That split should be completed by June 2.

At the beginning of 2007, the hundred-year-old company name Organon disappeared from the Netherlands, where the drug manufacturer in Oss once started. Last year it was announced that the company name will definitely return to the Netherlands. About 1,100 employees of drug company MSD Netherlands are making the switch to Organon. The pharmaceutical company is expected to employ 10,000 to 11,000 employees worldwide.

Hometown Oss will become the main production location of the renewed Organon in the Netherlands. That location will be led by Wenny Raaijmakers, who is already director of the location under the MSD flag.

Merck was already included in the S&P 500 and remains so. Organon takes the place of the American oil company HollyFrontier. That company is moving back to the smaller S&P MidCap 400.

–